Assessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk

Simply Wall St.2025-12-05

Wondering if Abbott Laboratories is still worth buying after its long run as a healthcare blue chip, or if most of the upside is already priced in? Despite a modest slip of 2.4% over the last week and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589890538?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","is_english":true,"pubTime":"2025-12-05 19:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589890538","market":"sg","top_or_hot":-1,"title":"Assessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk","media":"Simply Wall St.","content":"<div>\n<p>Wondering if Abbott Laboratories is still worth buying after its long run as a healthcare blue chip, or if most of the upside is already priced in? Despite a modest slip of 2.4% over the last week and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-after-105-gains-and-dcf-pe-signals-amid-exa\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-05 19:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-after-105-gains-and-dcf-pe-signals-amid-exa><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering if Abbott Laboratories is still worth buying after its long run as a healthcare blue chip, or if most of the upside is already priced in? Despite a modest slip of 2.4% over the last week and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-after-105-gains-and-dcf-pe-signals-amid-exa\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B4R5TH58.HKD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-after-105-gains-and-dcf-pe-signals-amid-exa","article_id":"2589890538","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-after-105-gains-and-dcf-pe-signals-amid-exa","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589890538","pubTimestamp":1764934652,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering if Abbott Laboratories is still worth buying after its long run as a healthcare blue chip, or if most of the upside is already priced in?\nDespite a modest slip of 2.4% over the last week and being roughly flat over 30 days, the stock is still up 10.5% year to date and over the past year, hinting that long term sentiment remains constructive at around $125.40 per share.\nRecent headlines have focused on Abbott’s continued push in medical devices and diagnostics, alongside regulatory...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4585":"ETF&股票定投概念","ABT":"雅培","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU0058720904.USD":"联博国际健康护理基金A","BK4566":"资本集团","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","SG9999002232.USD":"Allianz Global High Payout USD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","EXAS":"精密科学","BK4592":"伊斯兰概念","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4504":"桥水持仓","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4568":"美国抗疫概念","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4588":"碎股","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SGXZ41872573.SGD":"ALLIANZ SGD INCOME PLUS \"AM\" (SGD) INC","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0122379950.USD":"贝莱德世界健康科学A2","BK4581":"高盛持仓","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC"},"translate_title":"在Exact Sciences交易谈判中上涨10.5%和DCF PE信号后评估雅培","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1.5,"EXAS":1.5,"ABT":1.5},"content_text":"Wondering if Abbott Laboratories is still worth buying after its long run as a healthcare blue chip, or if most of the upside is already priced in? Despite a modest slip of 2.4% over the last week and being roughly flat over 30 days, the stock is still up 10.5% year to date and over the past year, hinting that long term sentiment remains constructive at around $125.40 per share. Recent headlines have focused on Abbott’s continued push in medical devices and diagnostics, alongside regulatory updates and product approvals that reinforce its role in areas like cardiovascular care and diabetes management. This kind of steady operational progress helps explain why the market has been willing to look through short term volatility while keeping a premium on the shares. On our framework, Abbott scores a 3/6 on valuation checks, as shown in our valuation scorecard. Next, we will examine what different valuation methods imply for the stock, and then finish with a more holistic way to think about its true worth.  Abbott Laboratories delivered 10.5% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry. AdvertisementApproach 1: Abbott Laboratories Discounted Cash Flow (DCF) Analysis The Discounted Cash Flow model estimates what a company is worth by projecting its future cash flows and then discounting them back to today, using a required rate of return. For Abbott Laboratories, the model starts with last twelve months free cash flow of about $6.8 billion and incorporates analysts’ forecasts for the next few years, followed by more gradual, extrapolated growth thereafter. On this basis, Abbott’s free cash flow is projected to be around $6.9 billion to $7.0 billion a year by 2035, according to the 2 Stage Free Cash Flow to Equity model. Aggregating and discounting these projected cash flows gives an estimated intrinsic value of roughly $72.88 per share. With the stock trading near $125.40, the DCF result suggests Abbott is about 72.1% overvalued relative to its modeled cash generation. This implies investors are paying a substantial premium to the company’s projected fundamentals. Result: OVERVALUED Our Discounted Cash Flow (DCF) analysis suggests Abbott Laboratories may be overvalued by 72.1%. Discover 913 undervalued stocks or create your own screener to find better value opportunities. ABT Discounted Cash Flow as at Dec 2025 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Abbott Laboratories. Approach 2: Abbott Laboratories Price vs Earnings For established, profitable companies like Abbott, the price to earnings ratio is a useful way to gauge whether investors are paying a reasonable price for each dollar of current earnings. In general, faster growing and lower risk businesses tend to justify a higher, or premium, PE ratio, while slower growth or higher uncertainty call for a discount. Abbott currently trades at about 15.7x earnings, which is well below both the Medical Equipment industry average of roughly 28.9x and the broader peer group average of about 50.0x. At first glance, that might suggest the stock is inexpensive compared to competitors. However, Simply Wall St’s Fair Ratio framework goes a step further by estimating what PE Abbott should reasonably trade on, given its specific earnings growth outlook, profitability, size, industry dynamics and risk profile. On this basis, Abbott’s Fair Ratio is around 25.5x, meaning the shares trade at a meaningful discount to where they would sit if priced in line with these fundamentals. This indicates that the stock appears undervalued on a PE basis, even after considering growth and risk. Result: UNDERVALUED NYSE:ABT PE Ratio as at Dec 2025 PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1442 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Abbott Laboratories Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple but powerful way to connect your view of Abbott Laboratories’ future to a concrete fair value estimate. A Narrative is your story behind the numbers, where you make clear assumptions about future revenue, earnings and margins, and the platform automatically turns that story into a financial forecast and a fair value that you can compare to today’s price to decide whether to buy, hold or sell. Narratives are easy to use and live inside the Simply Wall St Community page, used by millions of investors, and they continuously update as new information, such as earnings results or deal news like the potential Exact Sciences acquisition, flows in. For example, one Abbott Narrative might assume mid single digit revenue growth, a 17.5% profit margin and a fair value near $122, while a more optimistic Narrative could lean on higher growth, stronger margins and a fair value closer to $159, neatly capturing how different investors can reasonably disagree, yet still work from a clear, structured framework. Do you think there's more to the story for Abbott Laboratories? Head over to our Community to see what others are saying! NYSE:ABT Community Fair Values as at Dec 2025  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589890538","isCrawlerRequest":true}